Patents Assigned to Mallinckrodt Inc.
  • Patent number: 7790144
    Abstract: Cyanine dye bioconjugates useful for diagnostic imaging and therapy are disclosed. The conjugates include several cyanine dyes with a variety of bis- and tetrakis (carboxylic acid) homologes. The compounds are be conjugated to bioactive peptides, carbohydrates, hormones, drugs, or other bioactive agents. The small size of the compounds allows more favorable delivery to tumor cells as compared to larger molecular weight imaging agents. The various dyes are useful over the range of 350 to 1,300 nm, the exact range being dependent upon the particular dye. The use of a biocompatible organic solvent such as dimethylsulfoxide helps to maintain the fluorescence of the compounds. The inventive compounds are useful for diagnostic imaging and therapy, in endoscopic applications for the detection of tumors and other abnormalities, for localized therapy, for photoacoustic tumor imaging, detection and therapy, and for sonofluorescence tumor imaging, detection and therapy.
    Type: Grant
    Filed: March 15, 2004
    Date of Patent: September 7, 2010
    Assignee: Mallinckrodt Inc.
    Inventors: Samuel Achilefu, Raghavan Rajagopalan, Richard B. Dorshow, Joseph Bugaj, Muthunadar P. Periasamy
  • Publication number: 20100216998
    Abstract: An improved method for producing apomorphine and derivatives thereof is provided. The method is a convenient ‘one-pot’ process, comprising the conversion of codeine into apomorphine without isolating the apocodeine intermediate. Use of water reactive scavengers, reagents that will react irreversibly with water, decreases side product formation and allows the use of milder reaction conditions. This one-pot synthesis of apomorphine from codeine provides a faster reaction with improved yields at temperatures lower as compared to conventional methods. The lower operating temperatures and less volatile reactants make the method particularly useful for large-scale manufacturing.
    Type: Application
    Filed: September 2, 2008
    Publication date: August 26, 2010
    Applicant: MALLINCKRODT INC.
    Inventor: Narayanasamy Gurusamy
  • Publication number: 20100216997
    Abstract: The present invention provides (+)-morphinanium N-oxide compounds or pharmaceutically acceptable salts thereof. The invention also provides processes for producing (+)-morphinanium N-oxides or pharmaceutically acceptable salts thereof from the corresponding tertiary N-substituted (+)-morphinan compound or pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 23, 2010
    Publication date: August 26, 2010
    Applicant: Mallinckrodt Inc.
    Inventors: Gary L. Cantrell, Peter X. Wang, Bobby N. Trawick, Christopher W. Grote, David W. Berberich, Hang Sun, Subo Liao
  • Publication number: 20100216996
    Abstract: The present invention provides (+)-morphinanium quaternary salts. The invention also provides processes for producing (+)-morphinanium quaternary salts from tertiary N-substituted (+)-morphinan compounds.
    Type: Application
    Filed: February 23, 2010
    Publication date: August 26, 2010
    Applicant: Mallinckrodt Inc.
    Inventors: Gary L. Cantrell, Peter X. Wang, Bobby N. Trawick, Christopher W. Grote, David W. Berberich
  • Publication number: 20100216995
    Abstract: The present invention provides (+)-morphinanium compounds comprising substituted 6-hydroxy or 6-amine groups. The invention also provides methods for inhibiting microglial activation by administering the compounds of the invention.
    Type: Application
    Filed: February 23, 2010
    Publication date: August 26, 2010
    Applicant: Mallinckrodt Inc.
    Inventors: Christopher W. Grote, Gary L. Cantrell, Peter X. Wang, Bobby N. Trawick, David W. Berberich
  • Publication number: 20100210843
    Abstract: The invention provides a process for the N-alkylation of normorphinan compounds to produce N-alkylated morphinan compounds. In particular, the process relates to the alkylation of a normorphinan compound by a carboxaldehyde in the presence of a reducing agent to form an N-alkylated morphinan.
    Type: Application
    Filed: February 17, 2010
    Publication date: August 19, 2010
    Applicant: Mallinckrodt Inc.
    Inventors: Edumnd C. Hudson, Sharon Woods
  • Patent number: 7771389
    Abstract: An auto purge for an intravenous contrast injector of the type having a motor which advances a plunger drive ram and configured for use with a pre-filled or user-filled syringe containing an approximate known amount of air including a processor which causes the motor to move and a memory storing a predetermined purge stop point representative of the approximate known amount of air in the syringe, the injector configured to automatically advance the plunger drive ram an amount substantially equal to the predetermined purge stop point representative of the approximate known amount of air contained in the syringe.
    Type: Grant
    Filed: March 7, 2005
    Date of Patent: August 10, 2010
    Assignee: Mallinckrodt Inc.
    Inventors: Keith M. Grispo, Frank M. Fago
  • Patent number: 7772565
    Abstract: A radiation-shielding assembly can contain any of multiple containers of different sizes in a predetermined, fixed location within the assembly. A clamping system in of the assembly is able to clamp any of the containers so that they are held in the same fixed location within the assembly. The containers, regardless of size, are always located in the desired position within the shield. The positive location is achieved with out the use of separate components not attached to the assembly.
    Type: Grant
    Filed: August 11, 2006
    Date of Patent: August 10, 2010
    Assignee: Mallinckrodt Inc.
    Inventor: David W. Wilson
  • Patent number: 7767194
    Abstract: Cyanine and indocyanine dye compounds and bioconjugates are disclosed. The present invention includes several cyanine and indocyanine dyes, including bioconjugates of the same, with a variety of bis- and tetrakis (carboxylic acid) homologues. The compounds of the invention may be conjugated to bioactive peptides, carbohydrates, hormones, drugs, or other bioactive agents. The small size of compounds of the invention allows favorable delivery to tumor cells as compared to larger molecular weight imaging agents. Further, use of a biocompatible organic solvent such as dimethylsulfoxide may be said to assist in maintaining the fluorescence of compounds of the invention.
    Type: Grant
    Filed: June 6, 2005
    Date of Patent: August 3, 2010
    Assignee: Mallinckrodt Inc.
    Inventors: Samuel I. Achilefu, Raghavan Rajagopalan, Richard B. Dorshow, Joseph E. Bugaj, Muthunadar P. Periasamy
  • Patent number: 7764983
    Abstract: Embodiments of the present invention relate to pulse oximeter systems and methods. Specifically, one embodiment includes an oximeter system including an oximeter sensor comprising a light emitting element configured to emit light having a wavelength, a light detector configured to receive the light, and a memory storing signal quality data that facilitates determining a quality of signals sent from the light emitting element to the light detector via the light. Further, the oximeter system may comprise an oximeter monitor, comprising a receiving circuit configured to receive the signal quality data from the oximeter sensor, and a processor configured to use the signal quality data to calculate an optical transmissivity of a material for the wavelength.
    Type: Grant
    Filed: June 1, 2006
    Date of Patent: July 27, 2010
    Assignee: Mallinckrodt Inc.
    Inventors: Paul D. Mannheimer, Michael E. Fein, Marcia Fein, legal representative
  • Patent number: 7758861
    Abstract: The present invention discloses dye-sulfenate derivatives and their bioconjugates for dual phototherapy of tumors and other lesions. The compounds of the present invention may contain either a mixture of Type 1 and Type 2 agents or a single entity that integrates both units in the same molecules. The compounds are designed to produce both Type 1 and Type 2 phototherapeutic effect at once using dual wavelength light source that will produce singlet oxygen and free radicals at the lesion of interest.
    Type: Grant
    Filed: March 21, 2006
    Date of Patent: July 20, 2010
    Assignee: Mallinckrodt Inc.
    Inventors: Raghavan Rajagopalan, Samuel I. Achilefu, Joseph E. Bugaj, Richard D. Dorshow
  • Publication number: 20100179327
    Abstract: A synthetic process for the preparation of amino acid esters such as methylphenidate and analogs thereof is disclosed. The process involves reacting an amino acid such as ?-phenyl-?-(2-piperidinyl)acetic acid or an analog thereof with an alcohol such as methanol in the presence of an acid and a water sequestrant such as trimethyl orthoacetate. In some embodiments, the water sequestrant is added to the reaction mixture after an initial period of esterification and then the reaction is allowed to continue. The ?-phenyl-?-(2-piperidinyl)acetic acid methyl ester or analog thereof is then isolated from the reaction mixture. In one variation of the process, the supernatant liquid may be recycled in subsequent runs to increase yield and product purity.
    Type: Application
    Filed: January 6, 2010
    Publication date: July 15, 2010
    Applicant: Mallinckrodt Inc.
    Inventors: Joseph P. Haar, JR., Carl J. Schaefer, Charles S. Kuivila
  • Patent number: 7753835
    Abstract: The present invention, in some embodiments, relates to radiation-shielding containers for housing radioactive materials. For example, some container assemblies of the invention include a body and a lid both including radiopaque material, and together defining a receiving space for radioactive material. Each of the body and lid has a closure surface that is in close proximity with the closure surface of the other when the container assembly is in a closed condition. The closure surfaces of these container assemblies may be configured such that they run substantially entirely at an angle to a local direction of radiation emanating from the radioactive material. In other words, these closure surfaces may be oriented such that they are misaligned with radiation emanating from within the container assembly. The present invention, in some embodiments, relates to devices for administration of radioactive material (e.g., radiopharmaceutical capsule) to patients.
    Type: Grant
    Filed: September 2, 2005
    Date of Patent: July 13, 2010
    Assignee: Mallinckrodt Inc.
    Inventors: Petrus Johannes Jozef Van Der Lee, Tim T. Horeman
  • Patent number: 7750187
    Abstract: There is disclosed a method for the crystallization of benzphetamine hydrochloride from an organic medium by the steps of removing water from the system to a very low level and then reducing the temperature of the organic medium to provide crystallization of the acid salt. In the event that crystallization does not occur upon lowering the temperature of the medium, it has been discovered that gentle heating of the organic medium results in crystallization of the acid salt. It has also been discovered that higher temperature crystallization has been provided by removal of methamphetamine from the composition. The crystalline benzphetamine hydrochloride can then be isolated by typical liquid/solid separation means such as filtration or centrifugation.
    Type: Grant
    Filed: November 2, 2005
    Date of Patent: July 6, 2010
    Assignee: Mallinckrodt Inc.
    Inventors: Dennis J. Kalota, Keith G. Tomazi
  • Publication number: 20100166864
    Abstract: The present invention relates to an oral pulse release pharmaceutical composition, which comprises a polymer matrix core, wherein at least one pharmaceutically active ingredient is distributed within the core and on the outer surface of the core. Amphetamine salts, among a number of other pharmaceutically active ingredients, can be formulated as a pharmaceutical composition described herein. The present invention also provides a method for preparing an immediate release component on a solid pharmaceutical formulation.
    Type: Application
    Filed: March 22, 2006
    Publication date: July 1, 2010
    Applicant: MALLINCKRODT INC.
    Inventors: Ashwini Gadre, Mark R. Benmuvhar, Brian Kai-Ming Cheng, Vishal Gupta, Cliff J. Herman
  • Publication number: 20100137598
    Abstract: The present disclosure generally relates to a process for converting a fused, tricyclic compound to a fused, tetracyclic compound that includes a furan ring therein. More particularly, the present disclosure related to a process for preparing a hydrocodone compound, or a compound structurally related thereto, and in particular (+)-hydrocodone, by subjecting a structurally corresponding sinomenine starting compound to a super acid-assisted furan ring closure reaction.
    Type: Application
    Filed: November 30, 2009
    Publication date: June 3, 2010
    Applicant: Mallinckrodt Inc.
    Inventors: Peter X. Wang, Tao Jiang, Subo Liao, Erin Moore
  • Patent number: 7728145
    Abstract: There is described a process for the purification of an impure preparation containing fentanyl by means of a reverse phase preparative chromatography process. A chromatographic column is loaded with a stationary phase, typically a silica particle having an organic ligand bound thereto. With a loading ratio of from about 50 to about 150 the impure preparation is acidified and passed through the column. The column is eluted with typically an aqueous solution of acetonitrile and the purified fentanyl is obtained in a specified cut.
    Type: Grant
    Filed: October 22, 2004
    Date of Patent: June 1, 2010
    Assignee: Mallinckrodt Inc.
    Inventor: Enrico Anthony Antonini
  • Patent number: 7727196
    Abstract: A contrast media injection system detects the absolute position of the syringe ram using a non-contact sensor. A series of magnets and Hall-Effect sensors may be used or an opto-reflective system. Illuminated knobs that are connected to the drive mechanism for the syringe ram rotate with the drive and provide visual feedback on operation through the illumination. Analog Hall-Effect sensors are used to determine the presence or absence of magnets that identify the type of faceplate being used. The faceplates include control electronics, connected to the powerhead through connectors, which may be interchangeably used by the two faceplates. The faceplate electronics include detectors for automatically detecting the capacity of pre-filled syringes.
    Type: Grant
    Filed: January 14, 2008
    Date of Patent: June 1, 2010
    Assignee: Mallinckrodt Inc.
    Inventor: Charles S. Neer
  • Patent number: 7725168
    Abstract: A contrast media injection system includes detects the absolute position of the syringe ram using a non-contact sensor. A series of magnets and Hall-Effect sensors may be used or an opto-reflective system. Illuminated knobs that are connected to the drive mechanism for the syringe ram rotate with the drive and provide visual feedback on operation through the illumination. Analog Hall-Effect sensors are used to determine the presence or absence of magnets that identify the type of faceplate being used. The faceplates include control electronics, connected to the powerhead through connectors, which may be interchangeably used by the two faceplates. The faceplate electronics include detectors for automatically detecting the capacity of pre-filled syringes.
    Type: Grant
    Filed: October 23, 2006
    Date of Patent: May 25, 2010
    Assignee: Mallinckrodt Inc.
    Inventors: Charles S. Neer, Jonathan D. Gibbs, John Kevin Bruce, Robert J. Ziemba, David M. Brooks, James R. Small, Gary S. Wagner
  • Patent number: D617910
    Type: Grant
    Filed: November 9, 2009
    Date of Patent: June 15, 2010
    Assignee: Mallinckrodt Inc.
    Inventors: Duane L. Horton, Andrew D. Speth